Your Health, We Care
Avoid co-administration of pralsetinib with strong or moderate CYP3A inhibitors, P-gp inhibitors, or agents that are both P-gp inhibitors and strong/moderate CYP3A inhibitors. If co-administration cannot be avoided, the dose of pralsetinib should be reduced. Avoid co-administration of pralsetinib with strong or moderate CYP3A inducers. If co-administration cannot be avoided, the dose of pralsetinib should be increased.
from FDA，2024.03
During treatment with pralsetinib, it is imperative that you inform your healthcare provider of any ···【more】
Recommended：272026-16-01
While certain medications should not be used together at all, in other cases, two different drugs ma···【more】
Recommended：282026-16-01
During treatment with pralsetinib, it is imperative that you inform your healthcare provider of any prescription drugs, over-the-counter medications, vitamins/minerals, herbal prod···【more】
Article source：Lucius LaosRelease date：2026-01-16Recommended：27
While certain medications should not be used together at all, in other cases, two different drugs may need to be administered in combination even if interactions are likely to occu···【more】
Article source：Lucius LaosRelease date：2026-01-16Recommended：28
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
